Michael Barbella, Managing Editor05.25.23
Ur24 Technology Inc. has won Medicare reimbursement approval for its TrueClr products that actively empty a patient’s bladder.
“This is a major financial step for hospitals, nursing homes, assisted-living facilities and at-home patients who will now be reimbursed for a large portion of the cost of this system—the only catheter of its kind in the world—which delivers the highest level of safety, efficiency, comfort and dignity to patients,” Ur24Technology Chief Operating Officer Victoria Suarez said.
In its decision, the U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, stated that Ur24Technology sought a new reimbursement code for its active catheter system because “existing codes do not adequately describe the product due to the fact that it is revolutionary.”
The external TruClr system eliminates catheter-associated urinary tract infections in hospitals, improves patient quality of life, and lowers health care costs, Suarez noted. Because TruClr products are reusable for up to a month, they provide significant savings over internal catheters, which must be replaced far more frequently.
Ur24 Technology has a strategic partnership with Miami-based DemeTECH Corp. to manufacture and distribute TrueClr products in the United States and internationally, using DemeTech’s network in 132 countries. The catheters have been showcased recently at major global health industry trade shows in Germany and the United Arab Emirates, and will be demonstrated for medical device distributors and hospitals in Chile.
Ur24Technology, Inc. is a privately held medical device company located in Southern California that was founded in 2016 by Landon Duval. Five different external catheter prototypes were researched, designed and developed, leading to the TrueClr external catheter range of products.
Headquartered in Miami, DemeTECH is a leader in surgical sutures, mesh, and bone wax. DemeTECH's N95 masks and TrueClr external catheters are made in the United States with American materials.
“This is a major financial step for hospitals, nursing homes, assisted-living facilities and at-home patients who will now be reimbursed for a large portion of the cost of this system—the only catheter of its kind in the world—which delivers the highest level of safety, efficiency, comfort and dignity to patients,” Ur24Technology Chief Operating Officer Victoria Suarez said.
In its decision, the U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, stated that Ur24Technology sought a new reimbursement code for its active catheter system because “existing codes do not adequately describe the product due to the fact that it is revolutionary.”
The external TruClr system eliminates catheter-associated urinary tract infections in hospitals, improves patient quality of life, and lowers health care costs, Suarez noted. Because TruClr products are reusable for up to a month, they provide significant savings over internal catheters, which must be replaced far more frequently.
Ur24 Technology has a strategic partnership with Miami-based DemeTECH Corp. to manufacture and distribute TrueClr products in the United States and internationally, using DemeTech’s network in 132 countries. The catheters have been showcased recently at major global health industry trade shows in Germany and the United Arab Emirates, and will be demonstrated for medical device distributors and hospitals in Chile.
Ur24Technology, Inc. is a privately held medical device company located in Southern California that was founded in 2016 by Landon Duval. Five different external catheter prototypes were researched, designed and developed, leading to the TrueClr external catheter range of products.
Headquartered in Miami, DemeTECH is a leader in surgical sutures, mesh, and bone wax. DemeTECH's N95 masks and TrueClr external catheters are made in the United States with American materials.